scholarly journals Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease

2021 ◽  
Author(s):  
Johanna E. Emmens ◽  
Jozine M. Maaten ◽  
Frank P. Brouwers ◽  
Lyanne M. Kieneker ◽  
Kevin Damman ◽  
...  
Keyword(s):  
Heart Failure ◽  
Failure Data ◽  
Stage Disease ◽  
End Stage ◽  
New Onset

A Review of Prognostic Tools in Heart Failure

2017 ◽  
Vol 35 (3) ◽  
pp. 514-522 ◽  
Author(s):  
Jennifer Treece ◽  
Hrak Chemchirian ◽  
Neil Hamilton ◽  
Manar Jbara ◽  
Venkataramanan Gangadharan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Palliative Medicine ◽  
Poor Prognosis ◽  
Advanced Heart Failure ◽  
Improve Quality ◽  
Stage Disease ◽  
End Stage ◽  
Patients With Poor Prognosis

A minority of patients with end-stage disease are referred to palliative medicine for consultation in advanced heart failure. Educating stakeholders, including primary care, cardiology, and critical care of the benefits of hospice and palliative medicine for patients with poor prognosis, may increase appropriately timed referrals and improve quality of life for these patients. This article reviews multiple tools useful in prognostication in the setting of advanced heart failure.

scholarly journals Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)

Heart ◽  
2007 ◽  
Vol 93 (8) ◽  
pp. 968-973 ◽  
Author(s):  
C. Torp-Pedersen ◽  
M. Metra ◽  
A. Charlesworth ◽  
P. Spark ◽  
M. A. Lukas ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Failure Data ◽  
Onset Diabetes ◽  
European Trial ◽  
New Onset

Burning issues in acute heart failure management

2019 ◽  
Vol 61 (6) ◽  
Author(s):  
J. A. Ker ◽  
K. Outhoff
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Chronic Heart Failure ◽  
Pulmonary Oedema ◽  
Acute Heart Failure ◽  
Heart Failure Management ◽  
Life Saving ◽  
End Stage ◽  
New Onset

In general, heart failure is the end-stage manifestation of cardiovascular disease and is an important and increasing cause of morbidity worldwide. Acute heart failure, whether of new onset or an exacerbation of chronic heart failure, causes sudden congestion, typically presenting as pulmonary oedema. The mortality associated with acute heart failure is extremely high. Potentially life-saving treatments and other burning issues are highlighted in this review.

Midodrine in end-stage heart failure

2020 ◽  
pp. bmjspcare-2020-002369
Author(s):  
Ariel Gonzalez-Cordero ◽  
Stephanie Ortiz-Troche ◽  
Juan Nieves-Rivera ◽  
Marcel Mesa-Pabón ◽  
Hilton Franqui-Rivera
Keyword(s):  
Heart Failure ◽  
Hospice Care ◽  
Left Ventricular ◽  
Ventricular Assist ◽  
Reduced Ejection Fraction ◽  
Stage Disease ◽  
Days Of Therapy ◽  
Left Ventricular Assist ◽  
Refractory Hypotension ◽  
End Stage

It is estimated that 5% of patients with heart failure (HF) will progress to end-stage disease refractory to medical therapy and might require prolonged hospitalisation with inotropic support. We present the case of a patient with end-stage HF who was admitted with cardiogenic shock. During his hospitalisation, he required prolonged intravenous vasopressor therapy due to refractory hypotension. He did not qualify for heart transplantation or left ventricular-assist device strategies. Midodrine was started as a last resort attempt to wean off vasopressors. After 5 days of therapy, the patient was weaned entirely off vasopressors and was discharged home for hospice care. By the time of discharge, he was tolerating low-dose carvedilol along with midodrine. We propose midodrine as a reasonable alternative for patients with end-stage HF with reduced ejection fraction and refractory hypotension, who are dependent on intravenous vasoactive drugs and are not candidates for advanced HF therapies.

scholarly journals High selenium levels associate with reduced risk of mortality and new onset heart failure: data from PREVEND

2021 ◽  
Author(s):  
Ali A. Al‐Mubarak ◽  
Niels Grote Beverborg ◽  
Navin Suthahar ◽  
Ron T. Gansevoort ◽  
Stephan J.L. Bakker ◽  
...  
Keyword(s):  
Heart Failure ◽  
Failure Data ◽  
Risk Of Mortality ◽  
High Selenium ◽  
Reduced Risk ◽  
New Onset

Localization of endothelial nitric oxide synthase in the normal and failing human atrial myocardium

1996 ◽  
Vol 54 ◽  
pp. 786-787
Author(s):  
Chi-Ming Wei ◽  
Margarita Bracamonte ◽  
Shi-Wen Jiang ◽  
Richard C. Daly ◽  
Christopher G.A. McGregor ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Nitric Oxide Synthase ◽  
Endothelial Nitric Oxide Synthase ◽  
Cardiac Tissues ◽  
Mammalian Tissues ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide

Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also may modulate cardiomyocyte inotropism and growth via increasing cGMP. While endothelial nitric oxide synthase (eNOS) isoforms have been detected in non-human mammalian tissues, expression and localization of eNOS in the normal and failing human myocardium are poorly defined. Therefore, the present study was designed to investigate eNOS in human cardiac tissues in the presence and absence of congestive heart failure (CHF).Normal and failing atrial tissue were obtained from six cardiac donors and six end-stage heart failure patients undergoing primary cardiac transplantation. ENOS protein expression and localization was investigated utilizing Western blot analysis and immunohistochemical staining with the polyclonal rabbit antibody to eNOS (Transduction Laboratories, Lexington, Kentucky).

Sign in / Sign up

Export Citation Format

Share Document